文献速递冠心病

非ST段抬高急性冠脉综合征极早期与标准侵入性评估治疗的比较

Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.
PubMed 文献 · Circulation · 2018-01-01

VERDICT试验将2147例非ST段抬高急性冠脉综合征患者随机分配至12小时内或48-72小时内行侵入性冠脉造影,中位随访4.3年显示极早期策略未改善总体主要终点(HR 0.92,95%CI 0.78-1.08),但GRACE评分>140者极早期治疗改善主要结局(HR 0.81,95%CI 0.67-1.01,交互P=0.023)。

要点

  • 极早期(12小时内)侵入性策略未改善NSTEACS患者长期总体临床结局。
  • GRACE评分>140的高危患者中,极早期侵入性治疗改善长期主要结局。
  • 极早期组造影中位时间4.7小时,标准组61.6小时。

核心结论

  • 极早期侵入性冠脉评估对比2-3天内侵入性策略未改善NSTEACS患者总体长期临床结局。
  • 在最高危患者中,极早期侵入性治疗改善长期结局。

研究设计与样本

  • VERDICT试验为随机对照试验,纳入哥本哈根首都地区临床疑似NSTEACS患者2147例。
  • 患者按1:1随机分配至12小时内或48-72小时内行侵入性冠脉造影。
  • 主要终点为全因死亡、非致死性再发心肌梗死、难治性心肌缺血住院或心力衰竭住院的复合终点。

主要发现

  • 极早期组(1075例)造影中位时间4.7小时,标准组(1072例)61.6小时。
  • 造影发现显著冠脉病变者中,极早期组88.4%、标准组83.1%接受血运重建。
  • 中位随访4.3年(IQR 4.1-4.4),主要终点极早期组296例(27.5%)、标准组316例(29.5%),HR 0.92(95%CI 0.78-1.08)。
  • GRACE评分>140者极早期策略改善主要结局,HR 0.81(95%CI 0.67-1.01),交互P=0.023。

关键数值与推荐

  • 极早期侵入性评估定义为诊断后12小时内行冠脉造影及可能的血运重建。
  • 标准侵入性 care 定义为48-72小时内行冠脉造影。
  • 高危定义为GRACE风险评分>140。

临床怎么用

  • NSTEACS患者常规不推荐强行12小时内侵入性评估,可按标准时间窗安排。
  • GRACE评分>140的高危NSTEACS患者可考虑极早期侵入性治疗以改善长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal timing of invasive coronary angiography (ICA) and revascularization in patients with non-ST-segment elevation acute coronary syndrome is not well defined. We tested the hypothesis that a strategy of very early ICA and possible revascularization within 12 hours of diagnosis is superior to an invasive strategy performed within 48 to 72 hours in terms of clinical outcomes. METHODS: Patients admitted with clinical suspicion of non-ST-segment elevation acute coronary syndrome in the Capital Region of Copenhagen, Denmark, were screened for inclusion in the VERDICT trial (Very Early Versus Deferred Invasive Evaluation Using Computerized Tomography) ( ClinicalTrials.gov NCT02061891). Patients with ECG changes indicating new ischemia or elevated troponin, in whom ICA was clinically indicated and deemed logistically feasible within 12 hours, were randomized 1:1 to ICA within 12 hours or standard invasive care within 48 to 72 hours. The primary end point was a combination of all-cause death, nonfatal recurrent myocardial infarction, hospital admission for refractory myocardial ischemia, or hospital admission for heart failure. RESULTS: A total of 2147 patients were randomized; 1075 patients allocated to very early invasive evaluation had ICA performed at a median of 4.7 hours after randomization, whereas 1072 patients assigned to standard invasive care had ICA performed 61.6 hours after randomization. Among patients with significant coronary artery disease identified by ICA, coronary revascularization was performed in 88.4% (very early ICA) and 83.1% (standard invasive care). Within a median follow-up time of 4.3 (interquartile range, 4.1-4.4) years, the primary end point occurred in 296 (27.5%) of participants in the very early ICA group and 316 (29.5%) in the standard care group (hazard ratio, 0.92; 95% CI, 0.78-1.08). Among patients with a GRACE risk score (Global Registry of Acute Coronary Events) >140, a very early invasive treatment strategy improved the primary outcome compared with the standard invasive treatment (hazard ratio, 0.81; 95% CI, 0.67-1.01; P value for interaction=0.023). CONCLUSIONS: A strategy of very early invasive coronary evaluation does not improve overall long-term clinical outcome compared with an invasive strategy conducted within 2 to 3 days in patients with non-ST-segment elevation acute coronary syndrome. However, in patients with the highest risk, very early invasive therapy improves long-term outcomes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02061891.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Kofoed KF, Kelbæk H, Hansen PR, et al. Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation. 2018. PMID: 30565996. doi:10.1161/CIRCULATIONAHA.118.037152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。